Table 1

Non-exhaustive list of publications on non-targeted HCV screening in the ER

AuthorsCountryPopulationTest usedScreenedPositive (anti-HCV)New positiveRNALinkageRef.
Bielen et alBelgium18–70 yearsStandard
(Abbott HCV 3.0R)
23661.31%5 (0.2%)Yes12 requiring linkage;
9 (75%) linked
12
Bundle et alUKAdultsStandard62112.4%13 (0.2%)Yes44 requiring linkage;
29 (66%) notified;
13 (30%) fully linked
13
Cieply et alUK≥18 yearsStandard (ARCHITECT, Abbott) on residual blood samples28332.0%Yes14
Schechter- Perkins et alUSA (Boston, MA)≥13 years undergoing phlebotomyStandard (ARCHITECT, Abbott)380813.2%63 (1.7%)Yes223 linkage attempted; 66 (29.6%) linked15
Cowan et alUSA
(Bronx, NY)
AdultsRapid test (OraQuick HCV rapid antibody, Orasure)1870.5%NoLinkage protocol in place16
Evans et alUK≥16 years undergoing phlebotomyStandard (ARCHITECT, Abbott)32122%10 (0.3%)No; HCV Ag18 requiring linkage; 14 (78%) linked17
Torian et alUSA (Bronx, NY)Adults, blood remnantsStandard (VITROS anti-HCV, Ortho-Clinical Diagnostics)49897.5%38 (0.8%)*Yes18
Bert et alGermany≥18 years, blood remnantsStandard10 2152.7%Yes95 patients contacted;
20 interested by investigations
19
Hsieh et alUSA (Baltimore, MD)>17 years, blood remnantsStandard (GENEDIA HCV ELISA 3.0, GreenCross Life Science)471313.8%204 (4.3%)Yes20
Lyons et alUSA (Cincinnati, OH)18–64 yearsStandard (ELISA kit for Human Hepatitis C, Biochain)92413.9%87 (9.4%)Yes21
O’Connell et alIreland≥18 years undergoing phlebotomyStandard88395.1%58 (0.7%)Yes58 new patients requiring linkage; 43 (74.1%) linked22
Vermehren et alGermany≥18 years blood remnantsStandard (Elecsys anti-HCV immunoassay, Roche and ARCHITECT anti-HCV, Abbott)28 8092.6%265 (0.9%)Yes535 to contact; 175 (33%) linked23
  • *Includes only RNA+.

  • ER, emergency room; HCV, hepatitis C virus.